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To the editor 
The effect of RDN on renal artery stenosis was not well investigated in Henry Krum and 
colleagues’ study
1
. Only 18 patients underwent angiography at 14–30 days, and 14 underwent 
magnetic resonance angiography at 6 months. Therefore, the follow-up rate was very low in 
this cohort of 153 patients. It was not reported that how many patients underwent renal artery 
imaging at 12, 24, and 36 months. Nor was reported the exact imaging method used at these 
time points. Ultrasonography has limitations in detecting renal artery stenosis.
2,3
  
It is of concern that estimated glomerular filtration rate (eGFR) decreased (p=0.05) and the 
creatinine concentrations in the serum progressively increased (p=0.05).
1
 In addition, the 
effect of RDN on renal function was not clearly described. 28 patients had a decrease in 
eGFR of more than 25% after RDN
1
. However, it was not reported how many patients were 
followed up at each time point; nor was reported to what extent the eGFR was decreased in 
each patient. It would be more informative if the authors could provide the eGFR values for 
these 28 patients over this 3-year follow-up in a table and also how many patients showed a 
clinically significant increase in creatinine concentrations at each time point. The authors can 
not conclude that RDN is safe. 
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